Most weight loss telehealth sites look identical until you read the fine print. The differences in pharmacy transparency, price, and physician oversight are large enough to matter.
Here is how a first-timer should think through the choices, and which eight providers actually hold up.
1. HealthRX
Start with the price. Compounded semaglutide from $99 a month, compounded tirzepatide from $149 a month, with free overnight shipping to all fifty states. That combination is genuinely rare in this category.
The pharmacy side is spelled out clearly: medications come from Manifest Pharmacy in Greer, South Carolina, a 503A facility operating under USP-797 standards with lot-by-lot tracking from compounding bench to your door. The facility holds LegitScript certification (certificate 50087439). You can verify that independently. Most telehealth brands do not name their compounding pharmacy at all.
A US board-certified physician reviews your intake form within roughly 24 hours. If approved, the medication ships overnight. No subscription traps, no hidden fees.
On efficacy, HealthRX references published clinical trial data rather than making its own claims. The SURMOUNT-1 trial showed tirzepatide participants lost around 21% of body weight at 72 weeks. The STEP 1 trial put semaglutide at roughly 15% at 68 weeks. These are the trial figures, not HealthRX’s own outcomes. Compounded medications are not FDA-approved, and that distinction matters.
For a beginner who wants low entry cost, a named pharmacy with verifiable credentials, and no guesswork on pricing, this is the clearest starting point in the list.
2. FormBlends
FormBlends earns a spot for a specific kind of buyer. Someone who wants to see the actual lab numbers before injecting anything.
The platform publishes per-product purity testing on its compounded GLP-1 medications, including HPLC purity percentages, mass spectrometry identity confirmation, and endotoxin sterility results, with the actual figures attached. That level of documentation is uncommon. Medications are dispensed through an FDA-registered 503A compounding pharmacy, and the clinician oversight model is similar to other telehealth providers here.
Pricing is higher than HealthRX. Semaglutide runs around $299 per vial, tirzepatide around $349. FormBlends does not ship to all 50 states, covering 47 of them. It also carries a broader peptide catalog covering recovery, longevity, and cognitive peptides under the same clinical model, which is useful if you want one provider for more than just a GLP-1.
FormBlends ranks second here, not first, because HealthRX beats it on price and reach. But if published purity data or peptide variety matters more to you than cost, FormBlends is the stronger fit.
3. Mochi Health
Mochi sits at compounded semaglutide from $99 a month and compounded tirzepatide from $199. What separates it from the cheapest cash-pay options is the clinical team. Mochi uses board-certified obesity medicine physicians, a specialty credential that goes beyond general telehealth practitioners. The monitoring is more structured than most. Good for beginners who want professional oversight woven into the process rather than bolted on.
4. Ro Body
Ro‘s membership starts at $39 for the first month, then $74 to $149 monthly. Medications are billed separately. The prior-authorization team is a real differentiator. Ro actively works to get branded medications covered through insurance, which means some patients end up paying significantly less than the sticker price on Wegovy or Zepbound. If your insurance has any GLP-1 coverage, Ro is worth a look before assuming cash-pay is your only option.
5. PlushCare
PlushCare charges about $19.99 a month for membership and offers same-day appointments. It focuses on branded medications and insurance billing rather than compounded options. After Novo Nordisk’s March 2026 settlement shifted several platforms away from compounded semaglutide, PlushCare’s insurance-first model started looking more stable for long-term planning. Beginners with decent prescription coverage should price this out.
6. Henry Meds
Henry Meds runs on a cash-pay compounded model, with first-month pricing around $179 to $249. Shipping is fast, typically 24 to 72 hours. The monitoring is lighter than Mochi or Calibrate. That suits someone who has already talked to their own doctor and mostly wants affordable access with quick delivery.
7. Found
Found charges around $99 a month for the platform, with medication billed separately. It layers in coaching and behavioral support alongside the prescription. Beginners who think habit change needs as much attention as medication will find the coaching component more developed here than at most price-comparable options.
8. Hims & Hers
After the March 2026 Novo settlement, Hims & Hers moved to branded medications. Injectable Wegovy runs around $299 a month through the platform, oral semaglutide around $249, Zepbound around $399. With insurance and a savings card, some users get down to $0 to $25 monthly. The brand recognition is high. The cash-pay price without insurance is steep compared to the compounded options above, but branded medications carry FDA approval that compounded ones do not.
*Note: Compounded medications mentioned above are not FDA-approved. GLP-1 medications require a valid prescription and physician evaluation. Pricing reflects publicly available figures as of mid-2026 and can change.*
Common Questions
What is the cheapest way to start a GLP-1 program through telehealth in 2026?
HealthRX and Mochi Health both offer compounded semaglutide from $99 a month, which is the lowest entry point in this list. Factor in shipping too. HealthRX includes free overnight shipping, which adds real value when some competitors charge separately for delivery and can push monthly costs noticeably higher.
Does it matter which compounding pharmacy a telehealth platform uses?
It matters more than most beginners expect. A 503A facility operating under USP-797 standards with independent lot testing is meaningfully different from one that publishes no documentation at all. HealthRX names Manifest Pharmacy and lists a verifiable LegitScript certificate number. FormBlends publishes HPLC purity data. Most platforms name nothing, which makes quality comparison impossible before you order.
If my insurance might cover a GLP-1, which of these platforms is worth trying first?
Ro Body is the clearest answer here. It has a dedicated prior-authorization team that actively pursues insurance coverage for branded medications like Wegovy and Zepbound, rather than defaulting you to cash-pay compounded options. PlushCare’s insurance-first model is also worth checking if you want same-day appointments alongside that billing approach.
How did the March 2026 Novo Nordisk settlement change what these platforms can offer?
The settlement accelerated the shift away from compounded semaglutide for several providers. Hims & Hers moved to branded medications entirely afterward. PlushCare’s existing insurance-and-branded focus became more stable by comparison. Platforms still offering compounded tirzepatide, like HealthRX and Mochi, were less directly affected because tirzepatide’s compounding status followed a separate regulatory timeline.
Is the physician oversight at these telehealth platforms actually meaningful, or mostly a formality?
It varies. Mochi Health uses board-certified obesity medicine physicians, a specialty credential with specific training in weight management that general telehealth practitioners do not hold. Found adds structured behavioral coaching on top of the prescription. At cash-pay compounded platforms focused on fast delivery, the clinical review is real but lighter. Beginners with complex health histories should weigh that difference carefully before choosing on price alone.
Sources
- FDA: 503A compounding pharmacy regulations and 2026 warning letters to telehealth companies
- LegitScript: Certified pharmacy verification database
- Tirzepatide weight-loss outcomes: Jastreboff et al., *New England Journal of Medicine*, 2022 (SURMOUNT-1)
- Semaglutide weight-loss outcomes: Wilding et al., *New England Journal of Medicine*, 2021 (STEP 1)
- Novo Nordisk / compounded semaglutide settlement reporting, March 2026 (Reuters, STAT News)
- Individual brand pricing pages, verified May-June 2026
By
